ANTIVIRAL COMPOSITION AGAINST CORONAVIRUS

The present invention relates to an antiviral composition against coronavirus. More specifically, the antiviral composition comprises an antibody or fragment thereof, comprising heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1, VH CDR2 represented by SEQ ID NO: 2, VH CDR3 represented by SEQ ID...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Won Keun, KIM, Tai Hyun, OH, Kwang Ji
Format Patent
LanguageEnglish
French
Korean
Published 10.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present invention relates to an antiviral composition against coronavirus. More specifically, the antiviral composition comprises an antibody or fragment thereof, comprising heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1, VH CDR2 represented by SEQ ID NO: 2, VH CDR3 represented by SEQ ID NO: 3, light chain CDR1(VL CDR1) represented by SEQ ID NO: 4, VL CDR2 represented by SEQ ID NO: 5, and VL CDR3 represented by SEQ ID NO: 6, thereby exhibiting an excellent antiviral effect against coronavirus, and an effect of preventing, treating, or ameliorating diseases caused by coronavirus. La présente invention concerne une composition antivirale contre le coronavirus. Plus particulièrement, la composition antivirale comprend un anticorps ou un fragment de celui-ci, comprenant une chaîne lourde CDR1 (VH CDR1) représentée par SEQ ID NO : 1, VH CDR2 représentée par SEQ ID NO : 2, VH CDR3 représentée par SEQ ID NO : 3, une chaîne légère CDR1 (VL CDR1) représentée par SEQ ID NO : 4, VL CDR2 représentée par SEQ ID NO : 5, et VL CDR3 représentée par SEQ ID NO : 6, présentant ainsi un excellent effet antiviral contre le coronavirus, et un effet de prévention, de traitement ou d'amélioration de maladies provoquées par un coronavirus. 본 발명은 코로나바이러스에 대한 항바이러스용 조성물에 관한 것으로, 보다 상세하게는 서열번호 1로 표시되는 중쇄 CDR1(VH CDR1), 서열번호 2로 표시되는 VH CDR2, 및 서열번호 3으로 표시되는 VH CDR3, 서열번호 4로 표시되는 경쇄 CDR1(VL CDR1), 서열번호 5로 표시되는 VL CDR2 및 서열번호 6으로 표시되는 VL CDR3을 포함하는 항체 또는 이의 단편을 포함함으로써 코로나바이러스에 대한 우수한 항바이러스 효과를 나타내고, 코로나바이러스에 의해 유발되는 질환의 예방, 치료 또는 개선 효과를 나타낸다.
AbstractList The present invention relates to an antiviral composition against coronavirus. More specifically, the antiviral composition comprises an antibody or fragment thereof, comprising heavy chain CDR1 (VH CDR1) represented by SEQ ID NO: 1, VH CDR2 represented by SEQ ID NO: 2, VH CDR3 represented by SEQ ID NO: 3, light chain CDR1(VL CDR1) represented by SEQ ID NO: 4, VL CDR2 represented by SEQ ID NO: 5, and VL CDR3 represented by SEQ ID NO: 6, thereby exhibiting an excellent antiviral effect against coronavirus, and an effect of preventing, treating, or ameliorating diseases caused by coronavirus. La présente invention concerne une composition antivirale contre le coronavirus. Plus particulièrement, la composition antivirale comprend un anticorps ou un fragment de celui-ci, comprenant une chaîne lourde CDR1 (VH CDR1) représentée par SEQ ID NO : 1, VH CDR2 représentée par SEQ ID NO : 2, VH CDR3 représentée par SEQ ID NO : 3, une chaîne légère CDR1 (VL CDR1) représentée par SEQ ID NO : 4, VL CDR2 représentée par SEQ ID NO : 5, et VL CDR3 représentée par SEQ ID NO : 6, présentant ainsi un excellent effet antiviral contre le coronavirus, et un effet de prévention, de traitement ou d'amélioration de maladies provoquées par un coronavirus. 본 발명은 코로나바이러스에 대한 항바이러스용 조성물에 관한 것으로, 보다 상세하게는 서열번호 1로 표시되는 중쇄 CDR1(VH CDR1), 서열번호 2로 표시되는 VH CDR2, 및 서열번호 3으로 표시되는 VH CDR3, 서열번호 4로 표시되는 경쇄 CDR1(VL CDR1), 서열번호 5로 표시되는 VL CDR2 및 서열번호 6으로 표시되는 VL CDR3을 포함하는 항체 또는 이의 단편을 포함함으로써 코로나바이러스에 대한 우수한 항바이러스 효과를 나타내고, 코로나바이러스에 의해 유발되는 질환의 예방, 치료 또는 개선 효과를 나타낸다.
Author KIM, Tai Hyun
KIM, Won Keun
OH, Kwang Ji
Author_xml – fullname: KIM, Won Keun
– fullname: KIM, Tai Hyun
– fullname: OH, Kwang Ji
BookMark eNrjYmDJy89L5WTQdPQL8QzzDHL0UXD29w3wD_YM8fT3U3B0d_T0Cw4BigX5-zkC5UODeRhY0xJzilN5oTQ3g7Kba4izh25qQX58anFBYnJqXmpJfLi_kYGRkYGxoaGxuaOhMXGqAN-FJ2g
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate 코로나바이러스에 대한 항바이러스용 조성물
COMPOSITION ANTIVIRALE CONTRE LE CORONAVIRUS
ExternalDocumentID WO2022031137A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2022031137A13
IEDL.DBID EVB
IngestDate Fri Aug 30 05:40:52 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
Korean
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2022031137A13
Notes Application Number: WO2021KR10460
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220210&DB=EPODOC&CC=WO&NR=2022031137A1
ParticipantIDs epo_espacenet_WO2022031137A1
PublicationCentury 2000
PublicationDate 20220210
PublicationDateYYYYMMDD 2022-02-10
PublicationDate_xml – month: 02
  year: 2022
  text: 20220210
  day: 10
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies NOVELGEN CO., LTD
RelatedCompanies_xml – name: NOVELGEN CO., LTD
Score 3.3582697
Snippet The present invention relates to an antiviral composition against coronavirus. More specifically, the antiviral composition comprises an antibody or fragment...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
FOODS OR FOODSTUFFS
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT
THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
Title ANTIVIRAL COMPOSITION AGAINST CORONAVIRUS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220210&DB=EPODOC&locale=&CC=WO&NR=2022031137A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-J0SkEp-FBsm22tD0O6friK_aDr5t5G06Qgihuu4r_vpXa6p70lObh8wOXud7m7ANxkKtOpmXGF5QVBgEK5YjLdUDjvmoXKMpNw4YcMwv5o0n2a9WYNeF_nwlR1Qr-r4ogoUTnKe1nd18t_J5ZTxVau7ugrDi0evHTgyDU61nUBYWRnOHDjyIls2bYRt8lh8ksjmkYMC7HSDhrSpggAdKdDkZey3FQq3iHsxsjvozyCxtuiBfv2-u-1FuwF9ZM3NmvpWx3DrRWm_tRPrGfJjoI4GvvCvyRZjxZC8BTHkii0kD4Zn8C156b2SME5539bnL9Emwskp9BE8M_PQGI9zgqe60aOtgMzqNkvDM4JJVyU1dTu29DZxul8O_kCDkRXRCFragea5ecXv0QlW9Kr6mx-ABwafJM
link.rule.ids 230,309,786,891,25585,76894
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8JADG8IGvFNUeMH6hLNEh8W2Q7YeCDm2Jib7iswkDfCdrfEaITIjP--vTmUJ94ubdL7SHrtr9f2AG7nTaYlxpwrLM0IApSEKwbTdIXzlpE12dwgXMQh_aDjjFtP0_a0Au_rWpiiT-h30RwRNSpFfc-L-3r5H8SyitzK1X3yiqTFgx33LLlEx5omIIxs9XuDKLRCUzZNxG1yMPzlEVUlOkWstINOdld02h9M-qIuZblpVOwD2I1Q3kd-CJW3RR1q5vrvtTrs-eWTNw5L7VsdwR0NYnfiDqknmaEfhSNXxJck-kgRgsdIG4YBRf54dAw39iA2HQXnnP1tcfYSbi6QnEAVwT8_BYm1Oct4qukp-g5MT4xOpnNOEsJFW021ewaNbZLOt7OvoebEvjfz3OD5AvYFS2Qkq80GVPPPL36JBjdPropz-gEfN3-G
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ANTIVIRAL+COMPOSITION+AGAINST+CORONAVIRUS&rft.inventor=KIM%2C+Won+Keun&rft.inventor=KIM%2C+Tai+Hyun&rft.inventor=OH%2C+Kwang+Ji&rft.date=2022-02-10&rft.externalDBID=A1&rft.externalDocID=WO2022031137A1